| Similar Articles |
|---|
 |
Bio-IT World
August 2005 |
Project Summaries Summaries of candidates for Bio-IT World's "Best Practices 2005" projects.   |
Bio-IT World
September 2006
Mike May |
Working Out the Flow Better management of workflow issues in biotech and pharma could change fundamental aspects of these sciences in the near future. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Bio-IT World
Jul/Aug 2006
Deb Janssen |
Managing the Microarray Data Mountain Genomic studies often involve thousands of samples and require hundreds of thousands of assays per sample. Microarray manufacturers are scurrying to satisfy researcher demands for increased array density, sample number, and content flexibility. |
Bio-IT World
September 2005
Kevin Davies |
Bringing Good Things to Informatics In interview with Nick Giannasi, Head of Informatics for GE Healthcare's Bio-Sciences division on how the company is shedding light on data integration in discovery and clinical trials. |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
CIO
October 15, 2001
Stephanie Overby |
Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age... |
Bio-IT World
May 19, 2004
Malorye Branca |
Attack of the Lab-Bots Robots are invading every aspect of discovery and development within pharmaceutical companies, from genotyping to high-throughput screening. |
Bio-IT World
November 2006
John Russell |
Pathway Pioneers Innovative uses for pathway tools and exciting results from early users are sprouting like mushrooms after a spring rain -- albeit following a few harsh winters. And the usually risk-averse pharmaceutical industry has led in adopting pathway tools. |
Bio-IT World
January 21, 2005
Kevin Davies |
A Vision for iScience Applied Biosystems president Catherine Burzik discusses integrated science, lab technology, and running a $2B business. |
Bio-IT World
January 21, 2005 |
Defining 'Integrative Genomics' Five experts from academia and industry discuss the burgeoning field of integrative genomics. |
Bio-IT World
Dec 2006/Jan 2007 |
Resolute in the New Year Industry leaders in areas from pharmacogenetics to cheminformatics found 2006 to be a year of important steps forward, but looked with even more anticipation to 2007: Allen D. Roses, SVP, Pharmacogenetics GlaxoSmithKline... etc. |
Bio-IT World
August 13, 2002
Malorye Branca |
The Proteomics Odyssey Efforts to map the constellation of protein interactions in humans gather momentum as companies vie to provide tools to capitalize on the potential of proteomics. But can proteomics prevail where some feel genomics has failed? |
Bio-IT World
February 2007 |
Bio*IT World's Coming Attractions 2007 Bio-IT World Conference & Expo preview -- Meet the Keynotes... Oracle Users... Systems are Go... Candid Camera... A Vital IT Alliance... Next Generation Informatics... etc. |
Bio-IT World
August 2005
Johan Bostrom |
Agilent Acquisitions Bolster Portfolio of Products A string of acquisitions is helping Agilent Technologies establish itself as a major player in informatics for analytical laboratories, and its expanding product portfolio has made it a serious player in laboratory analysis automation and software integration. |
Bio-IT World
March 10, 2003
Mark D. Uehling |
Technology Overload Inundated with new IT tools and mountains of data, the pharmaceutical industry struggles to pull it all together. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
April 15, 2003
Malorye Branca |
Beyond the Blueprint How will the wealth of data emanating from the human genome and allied technologies impact research on health and disease? |
Bio-IT World
July 11, 2002
Malorye Branca |
Deep Sequence Diving Like sailors of old, genomic data miners dream of discovering riches and fame. Given the recent improvements in analytics -- and a little more time -- they just might succeed. |
Bio-IT World
February 2006
Kevin Davies |
Curtain Opens on Life Sciences Expo Highlights of the upcoming Life Sciences Conference + Expo: Keynotes... Conference Tracks... Speakers... Educational workshops... etc. |
Bio-IT World
September 9, 2002
Malorye Branca |
The New, New Pharmacogenomics The field of pharmacogenomics proves valuable in the battle against toxicity and late-stage drug failure -- one of the pharmaceutical industry's biggest problems. |
Pharmaceutical Executive
December 1, 2011
George Baeder |
China's Future in Bioscience Will big investments in infrastructure carry the day in positioning China as a global drug innovation powerhouse? |
Chemistry World
July 2010
Anna Lewcock |
Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition. |
Pharmaceutical Executive
July 1, 2005
Ellen H. Julian |
What Pharma Wants From IT Today Indications that compliance and productivity issues reign over information technology (IT) budgets at pharma companies were verified in the 2005 Pharmaceutical Executive/Life Science Insights Information Technology Survey of nearly 850 US pharma companies. |
Bio-IT World
November 14, 2003
Jeff Augen |
Making Information-Based Medicine Work A confluence of scientific discovery and high-throughput technology has made information-based medicine possible -- and imperative. |
Bio-IT World
October 9, 2002
Malorye Branca |
The Path to Personalized Medicine The tactics have changed, sometimes dramatically, but hints of the promise of pharmacogenomics are finally starting to trickle in from studies of asthma, cancer, and drug response. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
Bio-IT World
April 15, 2003
Mark D. Uehling |
Target Elimination Industry and FDA scientists turn to databases, applications software, and laboratory chips to move the safest, most effective molecules into clinical trials. |
Bio-IT World
January 12, 2004
Kevin Davies |
The Ultimate Platform Firm Greg Lucier on determinism in drug development at Invitrogen |
Bio-IT World
March 2006
Robert M. Frederickson |
Integration, Robotics, and Automation The integration of instruments and technology is a key concept driving the development of advanced life-sciences laboratory automation. More sophisticated robotics are also increasingly being integrated into automated systems. |
Bio-IT World
July 2005
Kevin Davies |
Medicine Gets Personal Touch More genomics-based drugs are moving into development with others, such as new cancer drugs showcasing on the clinical pharmacogenics scene as outlined in the Advances in Genomic Medicine program of a recent world conference. |
Bio-IT World
April 2006
Kevin Davies |
Microsoft Forges BioIT Alliance The software giant's fledgling alliance aims to bring together companies from a cross-section of the industry -- from biotech and Big Pharma to equipment manufacturers and software developers -- to collaborate on technology that will speed drug discovery. |
Industrial Physicist
Aug/Sep 2003
Ineke Malsch |
Protein research calls for advanced instruments The science of protein interactions is becoming a major tool in biomedical and drug development research. Carrying out and advancing such studies more efficiently and effectively, however, will require new, cutting-edge instrumentation. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Bio-IT World
March 2006 |
Special Show Preview: It's Showtime! Highlights of the upcoming fifth annual Bio IT World conference: Decoding the Genome... The Six-Figure Sequence... E-Clinical Futures... etc. |
Bio-IT World
February 10, 2003
Salvatore Salamone |
Made in Manhattan A talk with the new head of the Computational Biology Center at Memorial Sloan-Kettering. |
Bio-IT World
March 8, 2005
Kevin Davies |
InforSense Approach to Data Sharing CEO Yike Guo discusses Shanghai's giant grid computing project to link scientists. |
Bio-IT World
January 21, 2005
Salvatore Salamone |
A Prescription for Information-Based Medicine TurboWorx president and CEO Jeff Augen not only combines computational and biology expertise, but also has a clear vision of how to advance life science discovery. |
Bio-IT World
November 2006
Alan S. Louie |
Signs of Life in Life Sciences IT Spending Pharmaceutical and other life science companies are confronting explosive growth in the volume of data being generated from R&D programs including high-throughput discovery instrumentation, molecular imaging (pre-clinical and clinical), and access to external data sources. |
Bio-IT World
December 15, 2003
Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials. |
Bio-IT World
August 15, 2005
John Russell |
Reasons for Optimism Submissions to the 2005 Bio-IT World Best Practices Awards Program included a description of a systems of hieroglyphic representations of proteins, a platform for integrative genomics, and a number of entries that saved man hours by utilizing client management tools. |
Bio-IT World
December 10, 2002 |
Craig Venter Unvarnished (part II) The former Celera CEO covers privacy, ESTs, and his new research institutes. |
Bio-IT World
August 13, 2002
Mark D. Uehling |
Clinical Trial Data Management: Tortured by Paper Reams of paper stuffed into boxes and shipped to the FDA by the truckload is hardly the best approach to drug approval. But what's the right way? |
IEEE Spectrum
March 2013
Eliza Strickland |
The Gene Machine and Me Ion Torrent's chip-based genome sequencer is cheap, fast, and poised to revolutionize medicine |
Bio-IT World
August 18, 2004
John Russell |
A Dozen Sparkling Gems A snapshot of deserving Best Practices Awards entries: Locus Pharmaceuticals... Children's Memorial Hospital, Chicago... XOMA... University of Texas Health Science Center... etc. |
Bio-IT World
November 12, 2002
James Golden |
The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success. |
The Motley Fool
July 26, 2007
Brian Orelli |
Affymetrix Advances New products and services should help Affymetrix regain market share. Yesterday, the company even announced a small second-quarter profit. |
Bio-IT World
Jul/Aug 2006
Kate McDonald |
The Next Generation in Sequencing Is SOLiD Applied Biosystems has completed the acquisition of genetic analysis company Agencourt Personal Genomics for $120 million, and hopes to bring the company's novel next-generation sequencing technology to market next year. |
Bio-IT World
February 2007
Robert M. Frederickson |
Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform. |
The Motley Fool
March 30, 2007
Ralph Casale |
Another Genetic Sequencer Gobbled Up Roche buys out second-generation sequencer 454 Life Sciences. Investors, take note. |
